FOXA1 is an independent prognostic marker for ER-positive breast cancer. - Wikidata - wikimedia - TriplyDB

FOXA1 is an independent prognostic marker for ER-positive breast cancer.

FOXA1 is an independent prognostic marker for ER-positive breast cancer.

http://www.wikidata.org/entity/Q42486962

about

Network insights into the genes regulated by hepatocyte nuclear factor 4 in response to drug induced perturbations: a review Epigenetic coordination of signaling pathways during the epithelial-mesenchymal transition Reduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice.The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.Switch in FOXA1 status associates with endometrial cancer progression Interrogating genomic and epigenomic data to understand prostate cancer FOXA1: master of steroid receptor function in cancer.Identification of sample-specific regulations using integrative network level analysis FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer.Molecular mechanisms regulating the hormone sensitivity of breast cancer.Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer MicroRNA-212 suppresses tumor growth of human hepatocellular carcinoma by targeting FOXA1.Screening of feature genes in distinguishing different types of breast cancer using support vector machine.FOXA1 represses the molecular phenotype of basal breast cancer cells Clinicopathological significance of forkhead box protein A1 in breast cancer: A meta-analysis.Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment Forkhead box protein A1 inhibits the expression of uncoupling protein 2 in hydrogen peroxide-induced A549 cell line.FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).Multidrug-resistant breast cancer: current perspectives.A functional variant rs4442975 modulating FOXA1-binding affinity does not influence the risk or progression of breast cancer in Chinese Han population.Chromatin landscape and endocrine response in breast cancer.Role of steroid receptor and coregulator mutations in hormone-dependent cancers.GalNAc-T4 putatively modulates the estrogen regulatory network through FOXA1 glycosylation in human breast cancer cells.The Estrogen Receptor α-Cistrome Beyond Breast Cancer.Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial.Transcription factors link mouse WAP-T mammary tumors with human breast cancer.Overexpression of forkhead box J2 can decrease the migration of breast cancer cells.TFAP2C expression in breast cancer: correlation with overall survival beyond 10 years of initial diagnosis.FoxA1 is a key mediator of hormonal response in breast and prostate cancer Paradoxical roles for FOXA1 in anti-estrogen resistance and as a luminal differentiation factor in breast cancer.A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard.FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.Low expression of Beclin 1 and elevated expression of HIF-1α refine distant metastasis risk and predict poor prognosis of ER-positive, HER2-negative breast cancer.Lack of both androgen receptor and forkhead box A1 (FOXA1) expression is a poor prognostic factor in estrogen receptor-positive breast cancers.MicroRNA-132 suppresses cell proliferation in human breast cancer by directly targeting FOXA1.Opposite roles of FOXA1 and NKX2-1 in lung cancer progression.Recurrent and functional regulatory mutations in breast cancer.The relationship between the expression of FOXA1 and GATA3 and the efficacy of neoadjuvant endocrine therapy.Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients.

P2860

Q28661727-EEB5AD4D-D557-4F76-AF59-387B775F49CF Q30415888-BAC80610-6906-4E01-B52F-58C0CFB5C36A Q30419961-D11B0D1D-60F4-4A0B-8A24-B15B92A5C81A Q30978083-254F7580-0E94-4B4F-88B5-7722502A707D Q33645463-E7BCE681-799A-40E3-B7BF-6BFDE2E882EF Q34125866-882B1600-018A-4C8F-A467-57BBD22CE641 Q35532767-86121135-C4E4-4FC5-8714-7492AED5F2F2 Q35583547-A2C7E175-D5DC-4A75-92CE-A1E69DA32D6C Q35602325-B739BCDF-4547-4769-9E7B-E5C633D3A129 Q35713360-7239655E-DEDF-494E-A9A1-38076BF8DA7F Q35949760-E75F199B-4987-4680-B479-1B6D27412313 Q35955257-5005AED2-58B9-4606-8C40-97AC2AFB469E Q36015125-14F49AAB-8CCF-4542-9A0F-0193AC96040B Q36020557-19055FD7-E566-4A39-A72F-1651059B3667 Q36953276-39BB0283-F0A5-45C1-9F72-B159397300B5 Q37003317-1AE9A338-7164-4901-B218-2143C657F775 Q37378870-0C9CDC48-5249-4FBA-88F7-3EEFB8400C2A Q37379842-17811385-1F27-4A17-9762-E26FE335D8E7 Q37565213-58B275B3-1478-4399-B36D-272C31D5A3F3 Q37593383-7885BE57-6585-4470-813B-1A88AF8C9A73 Q37697205-4D8F8FDE-CDEB-4B60-B55D-2E70FA1900EE Q38067765-30774E59-0AF5-44C0-9342-B892F0072FC4 Q38736287-E070E69F-9236-43CF-A32A-6A4E0645D20A Q38821749-3C365D40-5ED2-4799-99CF-103DD6D895A8 Q38917972-77141DDA-4A39-496B-9186-2301520A9377 Q38975595-7F6AA529-13C3-498D-A223-ECFDB7AFC232 Q39242906-1D3299CA-D1A8-472D-B4FA-EACBCA89D699 Q39375100-BE8B591C-2647-485D-AC07-5AC5CCDDE868 Q41598833-19031C9B-A093-4995-848A-E86FF21012C4 Q42174955-51C0A518-60E1-46E6-813C-5A17178248EE Q42199542-6A77A349-537C-42E0-980E-5C3A9BCBE572 Q42438922-22C994EF-4FBE-4F9B-B0A5-3B5C661D162E Q45212093-0ED02D3C-6E7B-4022-BFE2-91F4C6E10AE4 Q45266784-121C1EED-F9E4-4E19-AB99-32769C79080A Q47138636-BC13F6C2-B016-4AC8-9A10-3C4FB582B696 Q47799652-6E1BD88C-71EE-48FD-80A8-F7BE56F2F7C2 Q48632489-1412CD06-5936-4E86-B44D-C17AF59FA200 Q50918699-1BA4F4DA-7F04-41D2-81F7-BEBF0290044A Q51606753-BC259790-0A9A-444E-A861-97CB059C9150 Q53175662-BEFD2F6D-AAE4-405B-9A4C-EE720E870BC9

P2860

FOXA1 is an independent prognostic marker for ER-positive breast cancer.

http://www.wikidata.org/entity/Q42486962

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

FOXA1 is an independent prognostic marker for ER-positive breast cancer.

@en

FOXA1 is an independent prognostic marker for ER-positive breast cancer.

@nl

type

label

FOXA1 is an independent prognostic marker for ER-positive breast cancer.

@en

FOXA1 is an independent prognostic marker for ER-positive breast cancer.

@nl

prefLabel

FOXA1 is an independent prognostic marker for ER-positive breast cancer.

@en

FOXA1 is an independent prognostic marker for ER-positive breast cancer.

@nl

P1433

Q42486962-B0D4BEF6-2F99-4862-8756-C9F51F292167

P1476

Q42486962-86B93A7F-B8F2-4A99-BB0B-20E707D2AE3C

P2093

Q42486962-07EBAFCF-0827-4B65-943C-E594DDA5FCE2

Q42486962-22416DFD-E92A-43F1-A4DA-60DAAD0F22A8

Q42486962-5EC1BCB6-FD9A-4D17-A3A1-6B04DDD74423

Q42486962-89022E18-19FC-42A1-936D-BD313EB48915

Q42486962-A95BACE0-0275-42AD-8D14-2FD38330BA50

Q42486962-ED923AD7-673B-4956-80D3-3DECBD8164D5

P2860

Q42486962-131ABE14-F7CB-4906-80E7-8EBBE211E09A

Q42486962-1B791EBF-C053-424C-A804-3591DDF5690D

Q42486962-25279B15-C7AE-40AB-895E-7BE0338B7C08

Q42486962-2BF72342-7427-400C-885E-FFBEA8F61EA4

Q42486962-2C8D8DF6-6818-4B43-AF18-851B0DF64EAC

Q42486962-2D7392B0-A1A8-48A2-9CDB-2A5AC80BC4F5

Q42486962-2F78B880-881F-4DD9-9155-419C95561A33

Q42486962-45D4D520-8608-426A-8EBE-886B548A3EA6

Q42486962-5020B7E3-0121-4360-B84F-E140346A0055

Q42486962-59F6421E-A2EB-45F0-81FE-8B0E2A2F9CFF

P2888

Q42486962-4F3BCE85-A2F5-4D54-9583-F934F2E58D76

P304

Q42486962-88D7EEB7-E9F3-4F33-9949-E677E0DCED8D

P31

Q42486962-E01A9FDB-5810-405C-8703-D254E9858F7D

P356

Q42486962-3A515BA9-E99B-4A23-A000-A7179539F1BB

P407

Q42486962-03CDF194-054F-4A5E-AE71-898FAD2B1105

P433

Q42486962-AA8D25A3-95F5-4342-82DC-C894C3A5019D

P478

Q42486962-D81021BB-EF43-4CBE-8F82-0F88DF0BB861

P50

Q42486962-27F48E6D-8813-442E-BDEF-27D8F9F54177

Q42486962-5BD533D1-0FFA-4BCD-AA69-819797EAC9C0

P577

Q42486962-E71B9512-521E-469B-A63C-35A2FEB23DB3

P6179

Q42486962-C0A67D96-5F61-4F27-B674-6951269DB455

P698

Q42486962-4DC694C9-120E-4A20-B7CC-A7A0BBABEBBA

P356

S10549-011-1482-6

P1433

Breast Cancer Research and Treatment

P1476

FOXA1 is an independent prognostic marker for ER-positive breast cancer

@en

P2093

David Huntsman

http://www.w3.org/2001/XMLSchema#string

Jennifer Choo

http://www.w3.org/2001/XMLSchema#string

Rohit K Jain

http://www.w3.org/2001/XMLSchema#string

Samuel Leung

http://www.w3.org/2001/XMLSchema#string

Sunil Badve

http://www.w3.org/2001/XMLSchema#string

Torsten Nielsen

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours

BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27(Kip1)

From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response

GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland

Cell-type selective chromatin remodeling defines the active subset of FOXA1-bound enhancers

Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5

Molecular portraits of human breast tumours

Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1

Tissue microarrays for high-throughput molecular profiling of tumor specimens

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

P2888

s10549-011-1482-6

P304

881-890

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-011-1482-6

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

131

http://www.w3.org/2001/XMLSchema#string

P50

Harikrishna Nakshatri

P577

2011-04-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1045303095

http://www.w3.org/2001/XMLSchema#string

P698

21503684

http://www.w3.org/2001/XMLSchema#string